Literature DB >> 11694902

Cytokines and liver diseases.

H Tilg1.   

Abstract

Cytokines are pleiotropic peptides produced by virtually every nucleated cell in the body. In most tissues, including the liver, constitutive production of cytokines is absent or minimal. There is increasing evidence that several cytokines mediate hepatic inflammation, apoptosis and necrosis of liver cells, cholestasis and fibrosis. Interestingly, the same mediators also mediate the regeneration of liver tissue after injury. Among the various cytokines, the proinflammatory cytokine tumour necrosis factor-alpha (TNF-a) has emerged as a key factor in various aspects of liver disease, such as cachexia and/or cholestasis. Thus, antagonism of TNF-a and other injury-related cytokines in liver diseases merits evaluation as a treatment of these diseases. However, because the same cytokines are also necessary for the regeneration of the tissue after the liver has been injured, inhibition of these mediators might impair hepatic recovery. The near future will bring the exiting clinical challenge of testing new anticytokine strategies in various liver diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694902     DOI: 10.1155/2001/746736

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  26 in total

1.  Hepatic Overlap Syndrome Improved With Infliximab.

Authors:  Nir Hilzenrat; Esther Lamoureux; Albert Cohen; Murray Baron
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-02

2.  Sarcopenia in a mice model of chronic liver disease: role of the ubiquitin-proteasome system and oxidative stress.

Authors:  Fabián Campos; Johanna Abrigo; Francisco Aguirre; Bruno Garcés; Marco Arrese; Saul Karpen; Daniel Cabrera; Marcelo E Andía; Felipe Simon; Claudio Cabello-Verrugio
Journal:  Pflugers Arch       Date:  2018-06-20       Impact factor: 3.657

3.  Mx1 in Hematopoietic Cells Protects against Thogoto Virus Infection.

Authors:  Jan Spitaels; Lien Van Hoecke; Kenny Roose; Georg Kochs; Xavier Saelens
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

4.  MyD88-dependent recruitment of monocytes and dendritic cells required for protection from pulmonary Burkholderia mallei infection.

Authors:  Andrew Goodyear; Ryan Troyer; Helle Bielefeldt-Ohmann; Steven Dow
Journal:  Infect Immun       Date:  2011-10-24       Impact factor: 3.441

5.  Naofen promotes TNF-α-mediated apoptosis of hepatocytes by activating caspase-3 in lipopolysaccharide-treated rats.

Authors:  Jun-Hua Fan; Guo-Gang Feng; Lei Huang; Guo-Duo Tang; Hai-Xing Jiang; Jing Xu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

6.  Coexistence of hyperlipidemia and acute cerebral ischemia/reperfusion induces severe liver damage in a rat model.

Authors:  Wei-Hong Gong; Wen-Xia Zheng; Jun Wang; Shi-Hui Chen; Bo Pang; Xia-Min Hu; Xiao-Lu Cao
Journal:  World J Gastroenterol       Date:  2012-09-21       Impact factor: 5.742

7.  Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection.

Authors:  Angela Dolganiuc; Oxana Norkina; Karen Kodys; Donna Catalano; Gennadiy Bakis; Christopher Marshall; Pranoti Mandrekar; Gyongyi Szabo
Journal:  Gastroenterology       Date:  2007-08-02       Impact factor: 22.682

Review 8.  Fatigue in liver disease: pathophysiology and clinical management.

Authors:  Mark G Swain
Journal:  Can J Gastroenterol       Date:  2006-03       Impact factor: 3.522

9.  Propofol reduces liver dysfunction caused by tumor necrosis factor-α production in Kupffer cells.

Authors:  Jiazheng Li; Nobuhisa Kandatsu; Guo-Gang Feng; Jia-Zhen Jiang; Lei Huang; Hiroyuki Kinoshita; Shoshiro Okada; Yoshihiro Fujiwara
Journal:  J Anesth       Date:  2016-02-16       Impact factor: 2.078

10.  Foxa2-dependent hepatic gene regulatory networks depend on physiological state.

Authors:  Irina M Bochkis; Jonathan Schug; Nir E Rubins; Atul R Chopra; Bert W O'Malley; Klaus H Kaestner
Journal:  Physiol Genomics       Date:  2009-05-05       Impact factor: 3.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.